Endurance ad Resistance Training Exercise
BehavioralPatients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
NCT Number: NCT03335176
The aim of this study is to assess the feasibility and the effects of a 6-week telerehabilitation on the three domains of the International Classification of Functioning, Disability and Health in HIV-infected patients under highly active antiretroviral therapy (HAART).
HIV-infected patients were randomized either into an Endurance and Resistance Training Exercise (ERTE) group or a control (CON) group. Telerehabilitation was realized in a public fitness center, with online guidance and weekly telephone advice, 3 times per week for 6 weeks. Feasibility was determined by recruitment rate, retention rate and adverse events. Secondary outcomes were impact on body composition, inflammation and coagulation (C-reactive protein, D-dimer), physical fitness and quality of life (WHOQOL-HIV).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
Time frame: At study completion (after 6 weeks)
Number of eligible participants who enrolled in the program out of the number were recruited
Time frame: At study completion (after 6 weeks)
Percentage of patients lost to follow-up
Time frame: At study completion (after 6 weeks)
Percentage of patients who experienced one or more adverse events
Time frame: Assessments at baseline and at 6 weeks
Weight (kg) is measured by using a bioelectrical impedance analysis
Time frame: Assessments at baseline and at 6 weeks
Lean body mass (kg) is measured by using a bioelectrical impedance analysis
Time frame: Assessments at baseline and at 6 weeks
Lean body mass (kg) is measured by using a bioelectrical impedance analysis
Time frame: Assessments at baseline and at 12 weeks
C-reactive protein is measured by a blood test
Time frame: Assessments at baseline and at 12 weeks
D-dimer is measured by a blood test
Time frame: Assessments at baseline and at 12 weeks
CD4+ T cell counts is measured by a blood test
Time frame: Assessments at baseline and at 12 weeks
Viral load is measured by a blood test
Time frame: Assessments at baseline and at 6 weeks
Functional exercise capacity is measured by a 6-minute walk test
Time frame: Assessments at baseline and at 6 weeks
Flexibility is measured by Toe touch test and sit and reach test
Time frame: Assessments at baseline and at 6 weeks
Lower body muscular strength is measured by 30-s chair-stand test
Time frame: Assessments at baseline and at 6 weeks
Upper limb strength is measured by hand grip strength tool
Time frame: Assessments at baseline and at 6 weeks
Quality of life is measured by World Health Organization Quality of Life HIV Instrument
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Other
Feasibility and Benefit of a Telerehabilitation Program in Human Immunodeficiency Virus-infected Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03823209
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Cleveland, Ohio, United States
View Trial DetailsNCT06176859
ART, Acquired Immunodeficiency Syndrome
Durban, KwaZulu-Natal, South Africa
View Trial DetailsNCT02344680
Acquired Immunodeficiency Syndrome, Adenocarcinoma
Lusaka, Lusaka Province, Zambia
View Trial DetailsNCT04704336
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
St Louis, Missouri, United States
View Trial Details